Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 10:53 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 649–672 of 4,271 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: ADM Clear all

Conditions: Advanced Follicular Lymphoma
Interventions: Obinutuzumab, Bendamustine, Cyclophosphamide, Doxorubicin, Prednisone/Prednisolone/Methylprednisolone, Vincristine; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 114 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 7
States / cities: Boulder, Colorado • Bethesda, Maryland • Florham Park, New Jersey + 3 more

Conditions: Healthy Young Adults
Interventions: Writing; Behavioral
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years and older
Enrollment: 165 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Type 1 Diabetes, Celiac Disease
Interventions: Sera and whole blood sampling, Differential Gene Expression (DGE); Diagnostic Test
Lead sponsor: Sanford Health; Other
Eligibility: 0 Minutes to 17 Years
Enrollment: 33,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2031
U.S. locations: 4
States / cities: Bemidji, Minnesota • Bismarck, North Dakota • Fargo, North Dakota + 1 more

Conditions: Cancer, Carcinoma, Fallopian Tube Cancer, Gynecological Malignancies, Metastases, Oncology, Ovarian Cancer, Solid Tumors, Tumors
Interventions: A1: AMG 386 10 mg/kg + Liposomal doxorubicin, A3: AMG 386 15mg/kg + Liposomal doxorubicin, B1: AMG 386 10 mg/kg + Topotecan, B3: AMG 386 15mg/kg + Topotecan; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 9
States / cities: Tucson, Arizona • Sacramento, California • Orlando, Florida + 6 more

Conditions: Calciphylaxis
Interventions: EPN-701 (Oral), Placebo (Normal Saline); Drug
Lead sponsor: Sagar U. Nigwekar, MD, MMSc; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Aortic Stenosis, Heart Block, Aortic Insufficiency
Interventions: Electrophysiology Study; Diagnostic Test
Lead sponsor: Henry Ford Health System; Other
Eligibility: 18 Years and older
Enrollment: 126 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Magnetic Resonance Imaging
Interventions: Dexmedetomidine, Ketamine; Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 1 Year to 18 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Lymphoma
Interventions: filgrastim, cyclophosphamide, cytarabine, dexamethasone, doxorubicin hydrochloride, methotrexate, vincristine sulfate; Biological · Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 16 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2007
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Sarcoma, Kaposi, HIV Infections
Interventions: Bleomycin sulfate, Vincristine sulfate, Doxorubicin hydrochloride, Zidovudine, Sargramostim; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 14 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1993
U.S. locations: 5
States / cities: Los Angeles, California • Boston, Massachusetts • Buffalo, New York + 1 more

Conditions: Ischemic Stroke
Interventions: Not listed
Lead sponsor: Dr. M. Asif Taqi; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Thousand Oaks, California

Conditions: Asthma, PTSD
Interventions: Cognitive Processing Therapy, Psychotherapy, Targeted Asthma Education, General Asthma Education; Behavioral
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 361 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: Pre-Diabetes, Metabolic Syndrome, Type 2 Diabetes
Interventions: Lifestyle intervention and provider feedback; Behavioral
Lead sponsor: Cook County Health; Government
Eligibility: 18 Years and older
Enrollment: 114 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Overweight, Obesity
Interventions: Weight Watchers Online Program, Philips ActiveLink, Eating and Activity Newsletter; Behavioral · Device
Lead sponsor: The Miriam Hospital; Other
Eligibility: 18 Years to 70 Years
Enrollment: 270 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 2
States / cities: Providence, Rhode Island • Knoxville, Tennessee

Conditions: Tobacco Dependence
Interventions: Enhanced Web Assisted Tobacco Intervention, Basic Web Assisted Tobacco Intervention; Behavioral
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years and older
Enrollment: 1,452 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Diffuse Large B Cell Lymphoma (DLBCL)
Interventions: Polatuzumab Vedotin, Mosunetuzumab, Cyclophosphamide, Doxorubicin, Prednisone, Pegfilgrastim; Drug · Other
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 70 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Orthopedic Trauma Surgery Patients, Postoperative Pain, Opioid Use, Depression, Post-traumatic Stress Disorder (PTSD)
Interventions: Ketamine, standard general anesthesia; Drug
Lead sponsor: Texas Tech University Health Sciences Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 2
States / cities: Lubbock, Texas

Conditions: Sleep Apnea, Obstructive, Tonsillectomy, Adenoidectomy, Postoperative Complications
Interventions: Caffeine, Placebo; Drug
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 30 Months to 18 Years
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Kidney Calculi, Quality of Life
Interventions: Ureteroscopy, Percutaneous nephrolithotomy; Procedure
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Medication Adherence, Kidney Transplant
Interventions: mHealth Intervention; Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 14 Years to 21 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Solid Tumor, KRAS Mutation-Related Tumors
Interventions: NEROFE, Doxorubicin; Drug
Lead sponsor: Georgetown University; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Child Restraint Systems, Seat Belts
Interventions: Motivational Interviewing, Tailored brochure; Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 345 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 2
States / cities: Ann Arbor, Michigan • Flint, Michigan

Conditions: Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
Interventions: filgrastim, cisplatin, doxorubicin hydrochloride, gemcitabine hydrochloride, ifosfamide, conventional surgery, neoadjuvant therapy; Biological · Drug · Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Not listed
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2006
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Breast Cancer, Postoperative Pain, Anesthesia, Nerve Block
Interventions: PEC I/II blocks by anesthesiologist - pre-operative, PEC I/II blocks by surgeon - intra-operative; Procedure
Lead sponsor: Melinda Seering; Other
Eligibility: 18 Years to 80 Years · Female only
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Depressive Disorder, Treatment-Resistant
Interventions: Esketamine, Placebo, Duloxetine (Oral Antidepressant), Escitalopram (Oral Antidepressant), Sertraline (Oral Antidepressant), Venlafaxine Extended Release (XR) (New Antidepressant); Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 65 Years and older
Enrollment: 139 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 15
States / cities: San Diego, California • New Haven, Connecticut • Miami, Florida + 12 more

Search by objective public record fields.

An Open-Label, Single Arm Study of Obinutuzumab Short Duration Infusion in Patients With Previously Untreated Advanced Follicular Lymphoma

Campus Life Study: Harnessing Generativity Among Young Adults

General Population Level Estimation for Type 1 Diabetes Risk in Children During Routine Care Delivery

AMG386 Comb w. Either Pegylated Liposomal Doxorubicin or Topotecan Subjects w. Advanced Recurrent Epithelial Ovarian CR

Study of EPN-701 for the Treatment of Calciphylaxis

Conduction Disease After Transcatheter Aortic Valve Replacement

Dexmedetomidine and Ketamine in MRI

Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma

A Phase I Study of the Combination of Recombinant GM-CSF, AZT, and Chemotherapy (ABV) (Adriamycin, Bleomycin, Vincristine) in AIDS and Kaposi's Sarcoma

Ideal Sedation for Stroke Thrombectomy

Assessing Inflammatory and Behavioral Pathways Linking PTSD to Increased Asthma Morbidity in WTC Workers

Integrating Lifestyle Therapy for Diabetes Prevention Into Primary Care

Weight Watchers Online

Web Assisted Tobacco Intervention With Community Colleges

Mosunetuzumab and Polatuzumab Vedotin With Split-Dose CHP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma

Ketamine for Pain, Opioid Use, and Mental Health in Orthopedic Trauma Patients

The Effect of Caffeine on Postextubation Adverse Respiratory Events in Children With Obstructive Sleep Apnea (OSA).

Quality of Life in Kidney Stone Patients Undergoing Surgery

A Pilot Study of mDOT for Immunosuppressant Adherence in Adolescent Kidney Transplant Recipients

NEROFE and Doxorubicin in KRAS-mutated ST2-positive Solid Tumors

A Brief MI Intervention in the ED to Increase Child Passenger Restraint Use

Neoadjuvant Ifosfamide, Doxorubicin, Gemcitabine, and Cisplatin in Treating Patients Who Are Undergoing Radical Cystectomy for Locally Advanced Carcinoma (Cancer) of the Urothelium

Comparison of Pre-op and Post-op Pectoralis Nerve Block

A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression